TEW-7197 임상 개시
Jul 17, 2014EVENTSHit 2002
MedPacto, Inc. completed the fully executed site contract for one of three clinical sites for TEW-7197 in the USA on 18th July, 2014 (NCT02160106). TEW-7197 is the forefront asset of MedPacto's oncology pipeline and it is for cancer patients of solid tumors. The phase 1 trial is planned to complete in April of 2016.
|Next||미국임상, TEW-7197 암환자 투약|
|Previous||메드팩토, TEW-7197 미국 FDA 로부터 IND 승인|